difference in the operation. In the multivariate analysis, CRP at the end of treatment ($P = 0.028$) was found to be a predictive factor for successful treatment.

**Conclusion.** CBII is a rare disease but associated with high treatment failure. Prolonged antifungal treatment is essential for successful treatment of CBII, and CRP at the end of treatment is a key predictive marker of successful treatment.

**Disclosures.** All authors: No reported disclosures.

218. The Influence of Obesity on the Infection Risk of Prosthetic Joint Infection in the Geriatric Orthopedic Population
Allina Nocen, MPH1; Michael Henry, MD1; Celeste Russell, MPH3; Geoffrey Westrich, MD1; Barry Brauze, MD2 and Andy Miller, MD1; 1Complex Joint Reconstruction Center, Hospital for Special Surgery, New York, New York, 2Hospital for Special Surgery, New York, New York, 3Hospital for Special Surgery, New York, New York, 4Infectious Diseases, Weill Cornell Medical College, New York, New York

**Session:** 45. Clinical: Bone and Joint Infection
**Thursday, October 5, 2017: 12:30 PM**

**Background.** Prosthetic joint infection (PJI) is a dreaded complication of arthroplasty. PJI are more common in the elderly and are associated with a substantial increase in 5-year mortality risk. PJI risk may correlate with increasing body mass index (BMI). However, the effect of BMI on PJI risk in the elderly has not been evaluated, to our knowledge. We sought to evaluate this relationship in a cohort of geriatric arthroplasty patients at an orthopaedic specialty hospital.

**Methods.** A retrospective cohort of hip and knee arthroplasty patients (age <75) from 2009–2014 was identified through administrative hospital data using ICD-9 codes. Patients with a BMI <14 or >60 kg/m², height <142 or >200 cm, and weight <36 or >226 kg were excluded. The presence of infection was confirmed via chart review; all PJI cases met the musculoskeletal infection society criteria. TKA was defined as having a BMI <30. Univariate analyses were done using $\chi^2$ tests and adjusted models were assessed using logistic regression.

**Results.** 13,755 geriatric arthroplasty patients (6,408 total hip arthroplasties [THA] and 7,347 total hip arthroplasties [TKA]) were assessed. Mean age and BMI were 78.5 ± 9.4 years and 27.6 ± 4.3, respectively. In an unadjusted model, obesity was associated with infection in THA ($P = 0.02$), but not TKA ($P = 0.31$). This association remained after adjusting for age, sex, and diabetes. Obesity was associated with an increased risk of infection in THA ([OR = 1.89 (95% CI 1.12–3.21); $P = 0.02$). However, as with the unadjusted model, this relationship was not found in TKA ($P = 0.50$).

**Conclusion.** Obesity increases THR PJI risk in the elderly. However, no such association was found for TKA. Future studies are needed to quantify the compounded risk of obesity in the geriatric arthroplasty patient.

**Disclosures.** All authors: No reported disclosures.

219. Searching for Bacterial Pathogens in Pediatric Patients with Chronic Recurrent Multifocal Osteomyelitis Using 16S rRNA Quantitative Real-Time PCR
Justin Searns, MD; Infectious Diseases, Children’s Hospital Colorado, Aurora, Colorado

**Session:** 45: Clinical: Bone and Joint Infection
**Thursday, October 5, 2017: 12:30 PM**

**Background.** Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory disease in children that causes relapsing episodes of pain. Patients are treated with anti-inflammatory medications or immune-modulating agents. Increasing evidence suggests that CRMO is mediated by dysregulation of the interleukin-1 pathway, not a bacterial source. However, CRMO is often a diagnosis of exclusion, and patients occasionally receive antimicrobials for possible culture negative infectious osteomyelitis. Few prior studies have utilized molecular diagnostic techniques to identify bacterial pathogens in CRMO bone biopsies.

**Methods.** Musculoskeletal specimens sent for culture during routine clinical care were banked from patients admitted to Children’s Hospital Colorado from 6/2012 to 10/2016. On retrospective chart review, 28 specimens were collected from 16 patients ultimately diagnosed with CRMO. Specimens were processed and extracted prior to molecular testing. All samples underwent quantitative real-time PCR (qPCR) testing using bacterial load assays targeting the bacterial 16S rRNA gene.

**Results.** Mean age at time of sample collection was 9.2 years. CRMO diagnosis was made by bone and joint radiographic, and radiologic findings. All patients had pathology findings consistent with CRMO including lymphoplasmacytic infiltrate, focal necrosis, and/or marrow fibrosis. All patients had MRI findings consistent with CRMO. No patient had bacteria identified on Gram stain; 2/28 samples (7%) had bacterial growth on culture (both were coagulase-negative staphylococcus, felt to be contaminants). None of the 28 specimens met the threshold of bacterial load on qPCR testing to necessitate bacterial sequencing. None of the 16 patients were treated with antimicrobials and there were no readmissions for clinical worsening.

**Conclusion.** CRMO patients did not have bacteria identified on universal bacterial 16S rRNA testing. This finding further supports that CRMO patients do not require antimicrobial therapy. Future steps to exclude infectious pathogens in CRMO could include next-generation DNA sequencing.

**Disclosures.** All authors: No reported disclosures.

220. Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections
Allison Lastinger, MD1; Matthew Dietz, MD2; John Guilfoilse, MD3 and Arif K. Sarwari, MD, MSc, MBA4; 1Internal Medicine, West Virginia University, Morgantown, West Virginia, 2Orthopedics, West Virginia University, Morgantown, West Virginia, 3West Virginia University, Morgantown, West Virginia, 4Medicine, West Virginia University, Morgantown, West Virginia

**Session:** 45: Clinical: Bone and Joint Infection
**Thursday, October 5, 2017: 12:30 PM**

**Background.** As the population in the United States ages, the number of people who will require a joint arthroplasty is expected to rise dramatically. The most serious complication of this surgery is prosthetic joint infection (PJI) which can lead to long-term pain and even mortality. Biofilms play a major role in these infections, and studies have suggested that tigecycline may work better than other antimicrobials in the setting of biofilms. In this study, we examined our institution’s experience with using tigecycline to treat PJI.

**Methods.** This was a retrospective review of all adult patients with PJI treated at West Virginia University from January 2008 to March 2016 who received tigecycline for 50% or greater of the treatment course. Demographic data, rationale for tigecycline use, type of surgery, microbiologic data, outcome and complications were assessed. Failure was defined as need to return to the operating room for an infectious complication or persistent drainage from the joint.

**Results.** In total, 34 patients met inclusion criteria. The median age was 65 years, and 62% of the patients were female. The most common reason for tigecycline use was empiric therapy, but other reasons included antimicrobial allergies and resistant organisms. The antimicrobial was used as frontline therapy in 29 cases (85%), and the mean duration of tigecycline therapy was 38 days. The most common organisms isolated were methicillin resistant Staphylococcus aureus ($n = 7$), coagulase negative Staphylococcus ($n = 5$), and Enterococcus species ($n = 4$), but 12 cases (35%) were culture negative. Treatment success was documented for 21 cases (62%); though, there was limited follow-up (2 months or less) in four of the successful cases. Nausea and vomiting was the most common adverse event, occurring in three patients.

**Conclusion.** Tigecycline is a glycyclcycline approved for use in a variety of infections including intra-abdominal and skin soft-tissue infections, but little is known about its use in the treatment of PJI. We found that tigecycline is well tolerated even when given for 6 weeks duration. Twenty-one of the 34 patients (62%) met our definition of successful treatment outcome with tigecycline. More studies are needed to assess tigecycline use in the treatment of PJI.

**Disclosures.** All authors: No reported disclosures.

221. Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections: Safety and Outcome in a Cohort of 10 Patients
Tritian Ferron, MD, PhD; Cecile Poudouress, Resident1; Sylvain Goutelle, DPharm, PhD; Sebastien Lusvig, MD, PhD; Claire Triflaut-Fillit, MD; Fatima Daoud, MD, PhD; Michel-Henri Fessy, MD, PhD; Sabine Cohen, DPharm, PhD; Frederic Laurent, DPharm, PhD; Christian Chabert, MD, PhD; Florent Valour, MD, PhD4 and Lyon BJJ Study group; 1Inserm 1111, UCBLL, Hospices Civils de Lyon, Lyon, France, 2Hospices Civils de Lyon, Lyon, France, 3Orthopaedic Surgery, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France, 4ID Department, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France, 5Laboratory of Pharmacology and Toxicology, Hospices Civils de Lyon – Centre Hospitalier Lyon Sud, Pierre-Benite, France, 4Laboratory of Bacteriology, Regional Reference Center for Bji, Hospices Civils de Lyon, Lyon, France

**Session:** 45: Clinical: Bone and Joint Infection
**Thursday, October 5, 2017: 12:30 PM**

**Background.** Optimal surgical therapy could be sometimes non-feasible, especially for elderly population. Therefore, a medical therapy with long-term suppressive antibiotic therapy (PSAT) seems to be an option to prevent recurrence and prosthesis loosening. Subcutaneous (SC) administration of injectable intravenous antibiotics as PSAT could be a convenient way when oral treatment is not available to facilitate ambulatory care, even if this practice is considered as an “off-label” practice.

**Methods.** All patients receiving SC PSAT since 2010 were prospectively enrolled in a cohort study evaluating treatment modalities, efficacy, and safety. Success was defined by the absence of clinical signs of infection at the time of last follow-up.

**Results.** We included 10 patients (median age of 70 years, 6/10 male, 4/10 patients aged >80) presenting with 10 BJI and three chronic osteomyelitis. Six had pluriinfection and four had infections due to multidrug-resistant Gram-negative pathogens. Suboptimal surgery was performed in seven patients, and three received only antibiotics. All patients received induction therapy with continuous antibiotic treatment before SC PSAT. For nine patients, SC injections were delivered by a 50 mlml 30 minute gravity infusion of the antibiotic, using butterfly disposable needle. One patient received direct flash SC administration. The most frequent drug used was etrapenem ($n = 7$; 1–2 g/day), followed by ceftriaxone ($n = 2$; 1 g/day), and ceftazidime ($n = 1$; 2 g/day). The dose was adjusted depending on the result of the terminal blood concentration. Median duration of treatment was 6 months (from 1 to 58 months), corresponding to a total of about 5,000 SC injections. SC PSAT had to be discontinued for side effects in only two patients, including skin necrosis in the usual injection site. Patients did not report any adverse events. No changes in the level of international normalized ratio were noted.

**Conclusion.** SC PSAT appears to be a safe and effective alternative therapy when optimal surgical strategy is not feasible and when oral treatment is not available.